TG Therapeutics TGTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.92M+69.6% | $192.57M+78.0% | $161.71M+92.8% | $141.15M+92.1% | $120.86M+90.4% | ||
| $33.51M+116% | $38.14M+148% | $28.09M+201% | $18.94M+128% | $15.54M+186% | ||
| $171.41M+62.8% | $154.43M+66.4% | $133.62M+79.3% | $122.21M+87.5% | $105.32M+81.5% | ||
| 83.6%-3.5pp | 80.2%-5.6pp | 82.6%-6.2pp | 86.6%-2.1pp | 87.1%-4.3pp | ||
| $48.4M+4.4% | $41.19M+72.5% | $40.88M+103% | $31.78M+81.0% | $46.36M+41.7% | ||
| $88.22M+75.3% | $62.75M+61.0% | $63.37M+51.0% | $55.59M+43.3% | $50.33M+45.5% | ||
| $73.14M+89.0% | $50.73M+68.1% | $51.02M+53.6% | $43.54M+36.8% | $38.69M+39.7% | ||
| $170.12M+51.6% | $142.08M+81.6% | $132.34M+85.2% | $106.31M+64.4% | $112.23M+54.3% | ||
| $34.8M+304% | $50.49M+68.6% | $29.37M+136% | $34.84M+295% | $8.62M+193% | ||
| 17%+9.8pp | 26.2%-1.5pp | 18.2%+3.3pp | 24.7%+12.7pp | 7.1%+21.7pp | ||
| $7.67M+13.5% | $6.53M-7.5% | $6.72M-38.0% | $6.72M+68.9% | $6.76M+195% | ||
| -$14.43M-358% | -$5.4M-20.1% | -$3.46M+57.7% | -$3.92M-73.2% | -$3.15M-124% | ||
| -$9.15M— | $0+100% | —— | —— | -$0+100% | ||
| $20.36M+272% | $45.09M+77.2% | $25.91M+507% | $30.92M+372% | $5.47M+151% | ||
| $586K+43.6% | $0-100% | -$364.99M-94,169% | $2.73M+933% | $408K+1,307% | ||
| $19.78M+291% | $23.04M-1.3% | $390.9M+9,975% | $28.19M+310% | $5.06M+147% | ||
| 9.7%+5.5pp | 12%-9.6pp | 241.7%+237pp | 20%+10.6pp | 4.2%+21.1pp | ||
| $0.12+300% | $0.150.0% | $2.43+12,050% | $0.17+325% | $0.03+143% | ||
| $0.14+367% | $0.20+25.0% | $2.69+8,867% | $0.19+280% | $0.03+143% | ||
| 160.1M-1.7% | 161.4M+0.7% | 161M+0.2% | 162.6M+2.0% | 162.8M+11.3% | ||
| 144.4M-1.5% | 144.3M-0.7% | 145.4M+0.2% | 146.7M+1.4% | 146.7M+0.3% | ||
| $4.88M+46.4% | $3.63M+15.0% | $5.34M+76.2% | $4.32M+71.3% | $3.33M+35.8% | ||
| $15.08M+29.5% | $12.02M+36.8% | $12.35M+41.2% | $12.04M+73.0% | $11.64M+69.0% | ||
| $2.39M-33.7% | $1.13M-55.9% | $3.27M+22.5% | $2.79M+63.1% | $3.6M+309% | ||
| $43.52M+1.1% | $37.56M+81.3% | $35.54M+108% | $27.46M+82.7% | $43.03M+42.2% | ||
| $204.92M+69.6% | $192.57M+78.0% | $161.71M+92.8% | $141.15M+92.1% | $120.86M+90.4% | ||
| $34.8M+304% | $50.49M+68.6% | $29.37M+136% | $34.84M+295% | $8.62M+193% | ||
| $34.83M+304% | $50.52M+68.6% | $29.38M+136% | $34.86M+295% | $8.63M+193% | ||
| $34.83M+304% | $50.52M+68.6% | $29.38M+136% | $34.86M+295% | $8.63M+193% | ||
| 17%+9.9pp | 26.2%-1.5pp | 18.2%+3.3pp | 24.7%+12.7pp | 7.1%+21.7pp | ||
| $34.8M+304% | $50.49M+68.6% | $29.37M+136% | $34.84M+295% | $8.62M+193% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
